|  The
most up to date regulatory information and advice from:
•Dr
Barbara Davit, Acting
Director of the Division of Bioequivalence II from the office of
Generic Drugs from CDER/ FDA
•Ronald Bauer, AGES PharmMed, Austria
•Ivana Tasevska, State Institute for Drug
Control, Czech Republic
•Tamas L Paal, National Institute of Pharmacy,
Hungary
Industry
expert feedback from:
•Berthold
Lausecker, Group Head Development Bioanalytics Hoffmann
La Roche, Switzerland
•Sandra van Os, Synthon BV, The Netherlands
•Gerald Beuerle, ratiopharm GmbH, Germany
•Talia Buggins, AstraZeneca, UK
•Berthold Lausecker, Hoffmann La Roche, Switzerland
•Roy De Maesschalck, Johnson & Johnson
Pharmaceutical Research and Development, Belgium
•Kevin Ryan, Pfizer, UK |
Informa
Life Sciences
Bioequivalence
&
Bioavailability
(BEBA)
18-19 May 2010, Hotel Lev, Ljubljana, Slovenia
www.informa-ls.com/beba
Gain essential advice from regulatory experts on
the new bioequivalence & bioavailability guidelines for 2010!
Download the full agenda here
Dear
Colleague,
We
are very pleased to announce that Synchron
Research will be presenting at Informa Life Sciences’
Bioequivalence & Bioavailability 2010 conference AND
as a valued Synchron Research client we are offering
you an exclusive 25% discount off delegate fees when you register
to attend this event.
That’s up to £700 off the original price !
About
us: Synchron
Research Services Pvt Ltd. is a leading Clinical Research Organisation
(CRO) based in India, providing a broad range of clinical research
services (including bioequivalence & bioavailability testing)
to pharmaceutical and biopharmaceutical companies both domestically
and internationally.
What
we will be talking about?
Dr.
Shivprakash Rathnam, Managing Director will be talking
about
“The Importance of Emerging Countries- the Indian
Perspective”
Main
topics include:
·
Evolution of BA/BE companies in India.
· Regulatory status in India on Bioequivalence.
· Opportunities and pitfalls in conducting bioequivalence
studies in India.
· Essentials to know before outsourcing BA/BE studies to
India.
· Global perspective on Indian BA/BE capabilities compared
to other lucrative destination. |
| |
Why
should you attend BEBA 2010? – 4 compelling reasons!
1.
Gain
answers to your most pressing BEBA related questions from
4 different key regulatory body Experts, including, FDA, AGES PharmMed,
the Czech Republic State Institute for Drug Control and the Hungarian
National Institute of Pharmacy.
2.
Benchmark
yourself against the competition !
Learn from Industry experts’ own experiences;
•
Talia Buggins, Senior Scientist, AstraZeneca, UK
• Dr Mirjana Dacevic, Head of Department of Medical Affairs,
Galenika a.d., Serbia
• Dr Shivprakash Rathnam, Managing Director, Synchron Research
Services Private Limited, India
• Dr Gerald Beuerle, Head of Clinical Development, Ratiopharm
GmbH, Germany
• Gorkhn Sharma-Singh, Senior Scientist, PAR&D, AstraZeneca
R&D Alderley Park, UK
• Susana Almeida, Project Leader, Medical Department, Grupo
Tecnimede, Portugal, co-chair of EGA's bioequivalence working group,
Portugal
• Claudia Patricia Nepomuceno Domingues, Clinical Research,
Mantecorp, Brazil
• Kevin Ryan, Assiociate Research Fellow Analytical R&D,
Worldwide Pharmaceutical Sciences (WWPS), Pfizer, UK
• Berthold Lausecker, Hoffmann La Roche, Switzerland
3.
INTERACTIVE
Q&A Session: Have your say and discuss the
future of BEBA with our expert speaker panel and fellow delegates
about: “Evaluating the New Bioequivalence and Bioanalytical
Guidelines”
Do
you have any ideas for discussion/questions for our panel now? Feel
free to forward your questions and suggestions for discussion to
the conference producer, Sahera Hossain today: mailto:sahera.hossain2@informa.com
4.
NEW topic
for 2010 – Learn how to successfully conduct Bioequivalence
and Bioavailability studies in emerging markets; including Brazil
& India- Learn how to cut your costs and maintain successful
outsourcing relationships with partners from emerging markets
PLUS
x2 MUST ATTEND SESSIONS:
Pre-Conference Workshop:
Monday
17 May
“Design and Evaluation of BE Studies"
AND
Post-Conference Workshop:
Thursday 20 May
“IVIVC in Practice for New Chemical Entities and Generics”
Why
should you attend?
This is a fantastic opportunity to build on the knowledge you will
gain during the 2 day conference and to extend your networking chances
with professionals from the BEBA community.
Visit
the event website
to find out more!
|
